Public Release: 7-Jan-2015 Combined therapy can reduce chance of recurrence in women with small, HER2+ breast tumors

January 7, 2015 11:27 PM

16 0

BOSTON - In a phase 2 clinical trial, women with small (stage 1), HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted drug following surgery were highly unlikely to have the cancer recur within three years of treatment, investigators at Dana-Farber Cancer Institute and other institutions report in a paper published today by the New England Journal of Medicine.

The findings may help establish the therapy - which combines the chemotherapy agent paclitaxel and the targeted drug trastuzumab (Herceptin) - as the first standard treatment approach for this group of patients, the authors state.

Also read: Trump, Pompeo Offer Conflicting Versions of North Korea Talks

Read more

To category page